A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles

Henk J. Out, Ishay David, Raphael Ron-El, Shevach Friedler, Eliezer Shalev, Joel Geslevich, Jehoshua Dor, Adrian Shulman, Zion Ben-Rafael, Benjamin Fisch, Martha Dirnfeld

Research output: Contribution to journalArticlepeer-review

Abstract

The effect of 100 and 200 IU per day recombinant FSH (rFSH) on numbers of oocytes retrieved and the total dose used in ovarian stimulation before intracytoplasmic sperm injection was investigated in a double-blind, randomized multicentre trial. A total of 91 women was treated with a low-dose protocol and 88 with a high-dose regimen at five centres. For each started cycle, significantly more oocytes were retrieved in the 200 IU group than in 100 IU group (12.0 versus 5.7, P < 0.001); total rFSH consumption was 1121 and 1875 IU in the low- and high-dose groups respectively. Significant variations were noted between centres with regard to numbers of oocytes collected per started cycle, ranging from 2.8 to 7.2 in the 100 IU group and from 9.0 to 19.1 in the high-dose group. Exploratory analyses of secondary outcomes suggested there were no differences in vital pregnancy rates per started cycle (19.2 versus 16.9%) and per embryo transfer (26.2 versus 19.3%) in the low- and high dose groups respectively. There were four hospitalizations due to ovarian hyperstimulation syndrome, all in the 200 IU group.

Original languageEnglish
Pages (from-to)1104-1109
Number of pages6
JournalHuman Reproduction
Volume16
Issue number6
DOIs
StatePublished - 2001
Externally publishedYes

Keywords

  • ICSI
  • IVF
  • Puregon
  • Randomized clinical trial
  • Recombinant FSH

Fingerprint

Dive into the research topics of 'A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles'. Together they form a unique fingerprint.

Cite this